What is Leerink Partnrs’ Estimate for NBIX Q1 Earnings?

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) – Investment analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for Neurocrine Biosciences in a report issued on Wednesday, January 29th. Leerink Partnrs analyst M. Goodman anticipates that the company will earn $0.91 per share for the quarter. The consensus estimate for Neurocrine Biosciences’ current full-year earnings is $3.92 per share.

Several other research analysts have also recently issued reports on NBIX. Needham & Company LLC reissued a “hold” rating on shares of Neurocrine Biosciences in a report on Friday, December 20th. UBS Group lifted their price objective on Neurocrine Biosciences from $162.00 to $176.00 and gave the company a “buy” rating in a research note on Thursday. StockNews.com downgraded Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research note on Friday, November 1st. Wedbush reiterated an “outperform” rating and set a $148.00 price target on shares of Neurocrine Biosciences in a research report on Monday, December 16th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $190.00 price objective on shares of Neurocrine Biosciences in a research note on Monday, December 16th. Five analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $166.10.

Neurocrine Biosciences Trading Up 1.7 %

NBIX opened at $153.29 on Friday. Neurocrine Biosciences has a 12-month low of $110.95 and a 12-month high of $157.98. The firm has a 50 day moving average of $135.88 and a two-hundred day moving average of $131.44. The firm has a market capitalization of $15.52 billion, a PE ratio of 41.10 and a beta of 0.33.

Insiders Place Their Bets

In other news, insider Ingrid Delaet sold 1,091 shares of the firm’s stock in a transaction that occurred on Tuesday, December 17th. The shares were sold at an average price of $135.00, for a total transaction of $147,285.00. Following the completion of the sale, the insider now owns 2,507 shares in the company, valued at $338,445. This trade represents a 30.32 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Kevin Charles Gorman sold 146,105 shares of the company’s stock in a transaction that occurred on Monday, January 27th. The shares were sold at an average price of $149.46, for a total value of $21,836,853.30. Following the completion of the transaction, the director now owns 514,596 shares in the company, valued at $76,911,518.16. This represents a 22.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 214,799 shares of company stock valued at $31,513,583 in the last ninety days. 4.30% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Neurocrine Biosciences

A number of hedge funds have recently modified their holdings of NBIX. State Street Corp lifted its position in Neurocrine Biosciences by 11.7% in the third quarter. State Street Corp now owns 5,148,293 shares of the company’s stock valued at $593,186,000 after buying an additional 539,936 shares during the last quarter. Jennison Associates LLC boosted its position in shares of Neurocrine Biosciences by 145.1% during the 4th quarter. Jennison Associates LLC now owns 820,694 shares of the company’s stock worth $112,025,000 after purchasing an additional 485,894 shares during the period. Los Angeles Capital Management LLC increased its holdings in Neurocrine Biosciences by 639.6% in the 3rd quarter. Los Angeles Capital Management LLC now owns 420,748 shares of the company’s stock valued at $48,479,000 after purchasing an additional 363,863 shares during the last quarter. Braidwell LP raised its position in Neurocrine Biosciences by 20.9% in the third quarter. Braidwell LP now owns 917,674 shares of the company’s stock valued at $105,734,000 after purchasing an additional 158,665 shares during the period. Finally, BNP Paribas Financial Markets lifted its stake in Neurocrine Biosciences by 23.9% during the third quarter. BNP Paribas Financial Markets now owns 533,324 shares of the company’s stock worth $61,450,000 after purchasing an additional 102,715 shares in the last quarter. 92.59% of the stock is currently owned by hedge funds and other institutional investors.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.